Mustang Bio, Inc. (MBIO) financial statements (2021 and earlier)

Company profile

Business Address 2 GANSEVOORT STREET
NEW YORK, NY 10014
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9861346127
Cash and cash equivalents9861163527
Short-term investments  1826 
Restricted cash and investments11   
Receivables  00 
Prepaid expense  10 
Other undisclosed current assets11   
Total current assets:10063356127
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment887  
Restricted cash and investments1111 
Other noncurrent assets0000 
Other undisclosed noncurrent assets   1 
Total noncurrent assets:101082 
TOTAL ASSETS:11073436327
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:96531
Accounts payable42   
Other undisclosed accounts payable and accrued liabilities54531
Debt02   
Due to related parties01  0
Other undisclosed current liabilities  002
Total current liabilities:108643
Noncurrent Liabilities
Long-term debt and lease obligation214   
Long-term debt, excluding current maturities 12   
Operating lease, liability22
Liabilities, other than long-term debt  10 
Accounts payable and accrued liabilities  10 
Total noncurrent liabilities:21410 
Total liabilities:1122643
Stockholders' equity
Stockholders' equity attributable to parent9852366024
Common stock00000
Common stock, value, subscriptions852104
Additional paid in capital2761721139937
Accumulated deficit(185)(125)(79)(48)(17)
Total stockholders' equity:9852366024
TOTAL LIABILITIES AND EQUITY:11073436327

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Operating expenses(57)(46)(31)(32)(11)
Operating loss:(57)(46)(31)(32)(11)
Nonoperating income (expense)(3)(1)10(1)
Interest and debt expense(4)(2)(0)(0)(0)
Net loss:(64)(48)(31)(31)(13)
Other undisclosed net income attributable to parent42000
Net loss available to common stockholders, diluted:(60)(46)(31)(31)(13)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(64)(48)(31)(31)(13)
Comprehensive loss, net of tax, attributable to parent:(64)(48)(31)(31)(13)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: